Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optune with Nivolumab and Ipilimumab in Melanoma Brain Metastasis
NCT03903640Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2019
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Washington University School of Medicine. Primary endpoint: Intracranial Progression-free Survival at 6 months. Started Oct 2019; status: terminated.
Beyond the preview
Go deeper on NCT03903640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903640.